2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human
PAPER

1413 Pathogenic germline TINF2 variants define a long-telomere clonal hematopoiesis and cancer predisposition syndrome distinct from dyskeratosis congenita

Olisaemeka Ogbue, MBBS, Pankaj Pradeep2, Duc Tran, PhD3, Alejandro Ferrer, PhD4, Terra Lasho, PhD5, Jenna Fernandez, Ph.D.6, Christy Finke, BS7, Nickolas Steinauer, M.D., Ph.D.8, Tariq Kewan, MD9, Ajoy Lawrence Dias, MD10, Abhishek Avinash Mangaonkar, MBBS11, Alison A. Bertuch, MD, PhD12, Kelly Bolton, MD, PhD13, Mrinal M. Patnaik, MD, MBBS14
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Washington University School of Medicine, St. Louis, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Baylor College of Medicine, Houston, United States
13 Washington University School of Medicine, St. Louis, United States
14 Mayo Clinic, Rochester, Minnesota, United States

Introduction

Canonical TINF2 variants within the dyskeratosis congenita (DC) hotspot cause a short-telomere syndrome characterized by bone marrow failure. In contrast, recurrent pathogenic variants outside the DC hotspot have emerged as candidate long-telomere alleles, analogous to germline POT1 loss-of-function variants that cause cancer predisposition with long telomeres (CPLT). We hypothesized that recurrent pathogenic germline TINF2 variants (NM_001099274.3) underlie a distinct long-telomere syndrome characterized by elongated telomeres, clonal hematopoiesis (CH), and cancer predisposition.

Methods

Whole-genome sequencing (WGS) from the All of Us Research Program (AoU; blood-derived DNA; n=414,830) served as the population-based discovery cohort. An independent validation cohort was derived from 150,246 Mayo Clinic participants who underwent whole exome sequencing. Rare germline TINF2 variants (gnomAD MAF <0.001) were curated according to ACMG criteria and grouped by predicted protein consequence (missense, nonsense, splice-site, and in-frame indel). Variants meeting pathogenic/likely pathogenic (P/LP) criteria were compared with rare missense variants of uncertain significance (VUS). Leukocyte telomere length (LTL) was estimated from WGS using TelSeq (PMID: 24609383) and compared with 1:1 age- and ancestry-matched non-carriers using multivariable regression adjusted for age and CH status. CH was identified across 185 driver genes (variant allele frequency ≥2%) as previously described (PMID: 36652671). Malignancies were ascertained using ICD codes (AoU) and manual chart review.

Results

Among 414,830 AoU participants, 320 (0.077%) carried rare TINF2 variants, including 27 with recurrent P/LP variants (p.Arg265*, n=20; p.Pro431LeufsT31, n=7) and 293 harboring rare missense VUS. Compared with 320 matched non-carriers, P/LP carriers demonstrated significantly longer leukocyte telomere length (LTL) (age-adjusted β=+0.38 SD; 95% CI, 0.18–0.58; P<0.001), whereas individuals with VUS did not differ from controls.

CH was enriched among P/LP carriers compared with VUS (18.5% vs. 4.8%; age-adjusted OR 4.3; P=0.017) and consisted almost exclusively of canonical age-related myeloid driver mutations, including DNMT3A (n=3), TET2 (n=1), ASXL1 (n=1), and JAK2 (n=1). Median CH VAF was 19% (range, 14–75%), with 1 individual harboring multiple CH mutations. The JAK2-mutant individual had no blood count abnormalities or ICD-coded myeloproliferative neoplasm. Among P/LP carriers, overt hematologic malignancy was limited to a single myeloid neoplasm, and no constitutional bone marrow failure was identified; solid tumors (excluding non-melanoma skin cancer) were numerically enriched among P/LP carriers compared with VUS (18.5% vs. 7.8%; p=0.073).

In the validation cohort, 150 individuals with rare germline TINF2 variants were identified among 150,246 participants (0.1%). Solid tumors were significantly enriched in P/LP compared with VUS (43.1% vs. 23.5%; OR 2.46; 95% CI, 1.22–4.96; P=0.014), including  sarcoma, melanoma, glioma, prostate, papillary thyroid, breast, and lung cancers, recapitulating the broad cancer susceptibility observed in germline POT1-CPLT. Carriers of the adjacent nonsense variants p.Arg265* and p.Arg266* exhibited the highest prevalence of neoplastic manifestations within the cohort (8/13 [61.5%] vs. 40/137 [29.2%]; OR 3.88; P=0.027). Notably, both recurrent variants independently occurred in patients with soft-tissue sarcoma, extending prior observations implicating p.Arg265* in shelterin-associated sarcoma susceptibility. In contrast, the only patient with constitutional bone marrow failure harbored the canonical DC-hotspot variant p.Lys280Glu, consistent with its established short-telomere phenotype.

Conclusion

Across two independent cohorts, recurrent P/LP germline TINF2 variants define a distinct CPLT (long-telomere) syndrome characterized by constitutively elongated telomeres, canonical age-related CH, and increased cancer susceptibility, contrasting sharply with the bone marrow failure phenotype of classical DC. The marked enrichment of neoplastic manifestations among carriers of the recurrent p.Arg265*/p.Arg266* variants provides compelling genetic and clinical evidence supporting their pathogenicity and establishes these alleles as clinically actionable markers for hereditary cancer risk assessment, variant interpretation, and surveillance.

 

 

 

 

Olisaemeka Ogbue, MBBS: No relevant conflicts of interest to declare.